Gb Sciences identifies new cannabis-inspired blends such as

LAS VEGAS, Dec. 22, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapies that address cytokine release syndrome (CRS) caused by viral infections such as COVID-19 and others. Over the two-year pandemic, more than 540 million people worldwide contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects associated with this viral infection, which inspired GB Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses.

The global market size of anti-inflammatory therapies was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is projected to reach USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. GB Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for an initial human trial of these proprietary cannabinoid-containing formulations. A key differentiator of Gb Sciences’ CRS therapy is the opportunity for early intervention and prevention for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapy may also be beneficial for patients suffering from CRS as a side effect of some new cancer therapies, such as Bispecific T-cell engagement (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T cells. ).

“Our research shows promising results for the potential use of cannabinoids within cannabinoid-containing blends as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of some viruses. Our therapies inspired by cannabis were designed to restore the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself,” said Andrea Small-Howard, President and Chief Science Officer of GB Sciences.

Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic blends designed to reduce specific cytokine levels and pro-inflammatory processes triggered by viruses, while preserving immune function and cytokines needed to fight virus infections. GB Sciences recently released a white paper on their new development program titled “Using proprietary AI/ML technology, new cannabis-inspired blends are being developed as innovative anti-inflammatory therapies”; download it here.

A proof-of-concept study completed by Michigan State University researchers in 2021 found that Gb Sciences’ patented cannabis-inspired minimal essential blends (MEMs) reduced biomarkers of cytokine release syndrome. Gb Sciences’ MEM, containing two to three cannabinoids each, reduced levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the individual ingredients tested separately. The ratios of those cannabinoid molecules within MEM formulations also greatly affected their anti-inflammatory potential, the study reported.

For more information about GB Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired biopharmaceutical research and development company that creates proprietary disease-targeted formulations of cannabis and other plant-inspired therapeutic blends for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant inspired” active ingredients in its therapeutic blends are synthetic homologues that are identical to the original plant compounds but manufactured under current good manufacturing practices. Gb Sciences’ intellectual property portfolio contains six patents issued in the United States and three issued in the US. Gb Sciences has five preclinical-stage product development programs in its drug development pipeline, as well as 17 patent applications pending in the United States and 51 overseas. Parkinson’s disease is being prepared for a first clinical study in humans Gb Sciences’ ions for chronic pain, anxiety and depression are currently undergoing preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical trial data to support its complex blends for the treatment of cytokine release syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. GB Sciences R&D production network includes distinguished universities, hospitals and contract research organisations. For more information, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “may,” “should,” “anticipates,” “probably,” “believes,” and words of similar meaning may identify forward-looking statements. These statements are not historical facts, but represent only the Company’s beliefs regarding future events, many of which, by their nature, are inherently uncertain and beyond the Company’s control. It is possible that the Company’s actual results and financial condition could differ, even materially, from the anticipated results and financial condition set forth in these forward-looking statements. In addition, information regarding the Company and its business, including factors that could potentially materially affect the Company’s business and financial and other results, is contained in the Company’s filings with the Securities and Exchange Commission, available at address www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or correct any forward-looking statement to reflect events or circumstances that will occur thereafter or of which we subsequently become aware.

Contact information:
Alessio Quintal
[email protected]

Related images

Image 1

This content was published through the news release distribution service at Newswire.com.

  • Featured image for Gb Sciences

Add a Comment

Your email address will not be published. Required fields are marked *